GH Research PLC shares surged by 47.89% in pre-market trading, reaching a 20-day high, following positive developments regarding its drug GH001.
The significant price movement is attributed to the FDA clearance for GH001's clinical investigation, which allows for U.S. subject enrollment and marks a crucial step towards the planned Phase 3 trial in 2026. This news has heightened investor confidence in the company's ability to address treatment-resistant depression (TRD), especially given the promising results from the Phase 2b trial where GH001 demonstrated a 15.5-point reduction in MADRS scores.
As the company prepares for its upcoming Phase 3 trial, the positive market reaction reflects strong anticipation for GH001's potential impact on TRD treatment, which could lead to substantial market opportunities and revenue growth for GH Research.
Wall Street analysts forecast GHRS stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for GHRS is 28.60 USD with a low forecast of 19.00 USD and a high forecast of 35.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
6 Analyst Rating
Wall Street analysts forecast GHRS stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for GHRS is 28.60 USD with a low forecast of 19.00 USD and a high forecast of 35.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
6 Buy
0 Hold
0 Sell
Strong Buy
Current: 16.600
Low
19.00
Averages
28.60
High
35.00
Current: 16.600
Low
19.00
Averages
28.60
High
35.00
RBC Capital
Outperform
maintain
$33 -> $40
2026-01-23
New
Reason
RBC Capital
Price Target
$33 -> $40
AI Analysis
2026-01-23
New
maintain
Outperform
Reason
RBC Capital raised the firm's price target on GH Research to $40 from $33 and keeps an Outperform rating on the shares. Following the firm's Psychedelics Symposium and discussions with the management, payers, and doctors, RBC is increasingly optimistic on GH's long- term sales opportunity, with GH001, the analyst tells investors in a research note.
Cantor Fitzgerald
initiated
$25
2025-06-04
Reason
Cantor Fitzgerald
Price Target
$25
2025-06-04
initiated
Reason
Cantor Fitzgerald assumed coverage of GH Research with an Overweight rating and $25 price target. Data generated for psychedelics across a number of mental health disorders have been "transformational," and the unmet need is "enormous" and growing, the analyst tells investors in a research note. The firm says sees the psychedelic total addressable market ultimately reaching $50B per year, which would be roughly 1M-1.5M patients treated per year, still only modest penetration, and believes there is room for plenty of successful options and companies offering psilocybin and novel synthetic products.
Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for GHRS
Unlock Now
Guggenheim
Eddie Hickman
Strong Buy
Initiates
$32
2025-03-13
Reason
Guggenheim
Eddie Hickman
Price Target
$32
2025-03-13
Initiates
Strong Buy
Reason
Guggenheim analyst Eddie Hickman initiated coverage of GH Research with a Buy rating and $32 price target.
RBC Capital
Brian Abrahams
Buy
Initiates
$31
2025-03-07
Reason
RBC Capital
Brian Abrahams
Price Target
$31
2025-03-07
Initiates
Buy
Reason
RBC Capital initiated coverage of GH Research with an Outperform rating and $31 price target. The firm says the "dramatic" antidepressive effects observed in the Phase IIb study of GH001, the company's psychedelic with "many favorable properties" facilitating administration and delivery, should be replicable in Phase III and position the drug as a treatment of choice in the future paradigm. With the stock off its post-data highs, RBC sees a "compelling entry point." While the stock's major near-term catalysts may be more limited, there should be appreciation as GH's development progress ensues and enthusiasm for psychedelics continues to build, contends the firm.
About GHRS
GH Research PLC is a clinical-stage biopharmaceutical company. The Company is engaged in offering treatment for psychiatric and neurological disorders. The Company's pipeline includes GH001, GH002 and GH003. The Company focuses on developing its 5- Methoxy-N, N-Dimethyltryptamine, (5-MeO-DMT), therapies for the treatment of patients with Treatment Resistant Depression (TRD). Its product candidate, GH001, is formulated for 5-MeO-DMT administration via an inhalation approach. With GH001, the Company has completed two Phase 1 healthy volunteer clinical trials and a Phase 1/2 clinical trial in patients with treatment-resistant depression (TRD). The GH002 is a 5-MeO-DMT product candidate formulated for administration via an injectable approach. GH002 has completed pre-clinical development to support early clinical trials. The GH003 is a 5-MeO-DMT product candidate formulated for administration via an intranasal administration approach.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
